Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 May;24(5):362-371.
doi: 10.1089/dia.2021.0514. Epub 2022 Mar 14.

Current Status and Emerging Options for Automated Insulin Delivery Systems

Gregory P Forlenza  1 , Rayhan A Lal  2
Affiliations
Review

Current Status and Emerging Options for Automated Insulin Delivery Systems

Gregory P Forlenza et al. Diabetes Technol Ther. 2022 May.

Abstract

Combining technologies including rapid insulin analogs, insulin pumps, continuous glucose monitors, and control algorithms has allowed for the creation of automated insulin delivery (AID) systems. These systems have proven to be the most effective technology for optimizing metabolic control and could hold the key to broadly achieving goal-level glycemic control for people with type 1 diabetes. The use of AID has exploded in the past several years with several options available in the United States and even more in Europe. In this article, we review the largest studies involving these AID systems, and then examine future directions for AID with an emphasis on usability.

Keywords: Artificial pancreas; Automated insulin delivery; Hybrid closed loop; Type 1 diabetes.

PubMed Disclaimer

Conflict of interest statement

G.P.F. conducts research supported by Medtronic, Dexcom, Abbott, Insulet, Tandem, Lilly, and Beta Bionics and has served as a speaker, consultant, or advisory board member for Medtronic, Dexcom, Abbott, Insulet, Tandem, Lilly, and Beta Bionics. R.A.L. consults for Abbott Diabetes Care, Biolinq, Capillary Biomedical, Deep Valley Labs, Morgan Stanley, Provention Bio, and Tidepool.

References

    1. The Diabetes Control and Complications Trial Research Group; Nathan DM, Genuth S, Lachin J, et al. : The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977–986. - PubMed
    1. Miller KM, Foster NC, Beck RW, et al. : Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D exchange clinic registry. Diabetes Care 2015;38:971–978. - PubMed
    1. Foster NC, Beck RW, Miller KM, et al. : State of type 1 diabetes management and outcomes from the T1D exchange in 2016–2018. Diabetes Technol Ther 2019;21:66–72. - PMC - PubMed
    1. Miller KM, Beck RW, Foster NC, Maahs DM: HbA1c levels in type 1 diabetes from early childhood to older adults: a deeper dive into the influence of technology and socioeconomic status on HbA1c in the T1D exchange clinic registry findings. Diabetes Technol Ther 2020;22:645–650. - PMC - PubMed
    1. Laffel LM, Kanapka LG, Beck RW, et al. : Effect of continuous glucose monitoring on glycemic control in adolescents and young adults with type 1 diabetes: a randomized clinical trial. JAMA 2020;323:2388–2396. - PMC - PubMed

Publication types